Publication Name	World Journal of Hepatology
Manuscript ID	19839
Country	Argentina

Received	2015-05-23 13:06
Peer-Review Started	2015-05-25 22:29
To Make the First Decision	2015-08-16 17:23
Return for Revision	2015-08-29 13:50
Revised	2015-09-01 08:30
Second Decision	2016-01-28 17:17
Accepted by Journal Editor-in-Chief	2016-01-30 22:11
Accepted by Executive Editor-in-Chief	2016-03-09 12:09
Articles in Press	2016-03-09 12:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-10 09:59
Publish the Manuscript Online	2016-03-15 11:19

ISSN	1948-5182 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Minireviews
Article Title	Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations
Manuscript Source	Invited Manuscript
All Author List	Fernando Bessone and Melisa Dirchwolf
Funding Agency and Grant Number
Corresponding Author	Fernando Bessone, MD, Full Professor of Gastroenterology, Department of Gastroenterology and Hepa­tology, School of Medicine, University of Rosario, Urquiza 3100, Rosario 2000, Argentina. bessonefernando@gmail.com
Key Words	Anti-tumor necrosis factor-α drugs; Acute liver failure; Biologic therapy; Immunosuppressive therapy; Hepatitis B
Core Tip	Chronic hepatitis B surface antigen carriers have a high risk to develop hepatitis B virus (HBV) reactivation (HBVr) when exposed to immunosupresive therapy. The loss of immune control in these patients may results in an increase in HBV replication. There is a wide spectrum of associated drugs with specific and stratified risk for the development of HBVr. Currently, HBVr incidence seems to increase worldwide, mainly due to the appearance of more powerful immunosuppressive drugs. This review article focus on when to treat, when to monitor, what patients should receive HBV therapy, and what drugs should be selected in each scenario. We updated here current HBV management guidelines.
Publish Date	2016-03-15 11:19
Citation	Bessone F, Dirchwolf M. Management of hepatitis B reac­tivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394
URL	http://www.wjgnet.com/1948-5182/full/v8/i8/385.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i8.385

Full Article (PDF)	WJH-8-385.pdf
Full Article (Word)	WJH-8-385.doc
Manuscript File	19839-Review.doc
Answering Reviewers	19839-Answering reviewers.pdf
Audio Core Tip	19839-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19839-Conflict-of-interest statement.pdf
Copyright License Agreement	19839-Copyright assignment.pdf
Institutional Animal Care and Use Committee Approval Form or Document	Institutional_Animal_Care_and_Use_Committee_Statement_20150523013550.doc
Peer-review Report	19839-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	19839-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	19839-Scientific misconduct check.pdf
Scientific Editor Work List	19839-Scientific editor work list.pdf